ADC Development
Antibody-drug conjugate (ADC) development focuses on the design and optimization of targeted therapeutics by integrating antibodies, linkers, and cytotoxic payloads to achieve improved therapeutic efficacy and controlled drug delivery. Protheragen provides comprehensive ADC development services, including process and analytical development, toxin and linker screening, and formulation development, supporting the optimization of ADC candidates from early research through clinical development.
Overview of ADC Development
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that combine monoclonal antibodies with highly potent cytotoxic payloads through specialized linker technologies. By utilizing the targeting capability of antibodies and the therapeutic activity of small-molecule drugs, ADCs are designed to selectively deliver cytotoxic agents to specific cells while minimizing off-target effects.
The development of ADCs involves the coordinated optimization of multiple critical components, including antibody selection, linker-payload design, conjugation strategy, drug-antibody ratio (DAR) control, purification processes, analytical characterization, and formulation development. A well-established ADC development process is essential for achieving product stability, consistent quality, and successful clinical translation.
Fig.1 Structure and mechanism of action of ADC. (Tsuchikama K, et al., 2018)
Our Services
Our comprehensive services cover every essential stage of biologics process development, enabling efficient process optimization from laboratory-scale development to manufacturing-ready processes.
Process & Analytical Development
ADC molecules require precise control of conjugation chemistry to achieve consistent product quality, optimal DAR distribution, and reproducible biological activity.
Our process development platform supports both conventional conjugation and site-specific conjugation technologies, enabling rapid development from feasibility studies to scalable manufacturing processes.
Toxin & Linker Screening
The selection of appropriate cytotoxic payloads and linker technologies is critical for ADC efficacy, stability, and safety.
Our ADC development platform provides diversified linker and payload screening capabilities to identify optimal combinations that improve target specificity, conjugation efficiency, and therapeutic performance.
Formulation Development
ADC molecules contain complex biological and chemical components, including antibodies, linkers, and cytotoxic payloads. Optimized formulation development is essential to maintain molecular integrity, stability, and therapeutic activity throughout storage and administration.
ADC Development Workflow
Protheragen supports ADC programs through an integrated development workflow, enabling systematic optimization from molecular design to clinical candidate preparation.
| Stage |
Capability |
| ADC Design |
Antibody, linker and payload strategy |
| Conjugation Development |
Chemical conjugation optimization |
| Process Development |
Reaction and purification optimization |
| Analytical Evaluation |
DAR, purity, structure and potency analysis |
| Formulation Optimization |
Stability and drug product development |
| Clinical Readiness |
Material preparation and technology transfer |
Applications
ADC development requires flexible strategies to address different therapeutic targets, molecular formats, and development challenges. Protheragen supports a broad range of ADC programs by providing customized development solutions from early feasibility assessment to clinical candidate optimization.
Novel ADC Candidate Development
ADC development requires systematic optimization of antibody, linker, and payload components to achieve balanced efficacy, stability, and developability.
Next-Generation ADC Development
Emerging ADC technologies require specialized development strategies to address challenges such as payload selection, conjugation control, and molecular stability.
Oncology ADC Programs
ADCs are widely investigated in oncology due to their ability to selectively deliver cytotoxic agents to tumor cells.
Early-Stage ADC Feasibility Studies
For early ADC projects, rapid evaluation of molecular feasibility and development potential is critical.
ADC Optimization and Development Advancement
For ADC candidates requiring further optimization, we provide targeted development support to improve product quality and development readiness.
Biosimilar ADC Development
The development of ADC biosimilars requires comprehensive understanding of the reference product, including antibody characteristics, linker-payload composition, conjugation profile, and critical quality attributes.
Why Choose Protheragen
- Integrated ADC Development Platform
Supporting multiple stages from linker-payload evaluation to formulation optimization.
- Comprehensive Analytical Support
Combining process understanding with advanced characterization approaches to evaluate ADC quality attributes.
- Flexible Development Strategies
Providing customized solutions according to different ADC molecules, targets, and development requirements.
- Accelerated Candidate Advancement
Helping partners efficiently progress ADC programs toward clinical development.
This integrated approach enables clients to establish robust, scalable, and regulatory-ready manufacturing processes while reducing development risk and accelerating the transition from research to clinical and commercial production.
Developing successful ADC candidates requires integrated expertise across antibody engineering, linker-payload selection, conjugation optimization, and formulation strategy. Protheragen combines multidisciplinary capabilities and flexible development solutions to support ADC programs at different stages, helping partners advance innovative molecules toward clinical development. Whether you are initiating a new ADC program or seeking optimization support for an existing candidate, our team provides tailored development strategies designed to improve product quality, stability, and development efficiency. Contact us for comprehensive ADC development solutions tailored to your project requirements.
Reference
- Tsuchikama K, et al. "Antibody-drug conjugates: recent advances in conjugation and linker chemistries" Protein Cell, 2018;9(1):33-46.
